These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Ben-Ami R; Lewis RE; Kontoyiannis DP Curr Opin Infect Dis; 2009 Aug; 22(4):376-84. PubMed ID: 19491674 [TBL] [Abstract][Full Text] [Related]
3. A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease. Ben-Ami R; Halaburda K; Klyasova G; Metan G; Torosian T; Akova M J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii25-33. PubMed ID: 24155143 [TBL] [Abstract][Full Text] [Related]
4. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Leather HL; Wingard JR Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028 [TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
6. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. Michallet M; Ito JI J Clin Oncol; 2009 Jul; 27(20):3398-409. PubMed ID: 19487382 [TBL] [Abstract][Full Text] [Related]
7. Current practice of antifungal prophylaxis and treatment in immunocompromised children and adults with malignancies: a single centre approach. Lehrnbecher T; Mousset S; Sörensen J; Böhme A Mycoses; 2009 Mar; 52(2):107-17. PubMed ID: 18983431 [TBL] [Abstract][Full Text] [Related]
8. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Girmenia C; Barosi G; Aversa F; Bacigalupo A; Barbui T; Baronciani D; Bosi A; Candoni A; Locasciulli A; Locatelli F; Menichetti F; Musso M; Viscoli C; Rambaldi A Clin Infect Dis; 2009 Oct; 49(8):1226-36. PubMed ID: 19772390 [TBL] [Abstract][Full Text] [Related]
9. Antifungal therapy strategies in hematopoietic stem-cell transplant recipients: early treatment options for improving outcomes. Chandrasekar P; Ljungman PT Transplantation; 2008 Jul; 86(2):183-91. PubMed ID: 18645475 [TBL] [Abstract][Full Text] [Related]
10. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. Pagano L; Akova M; Dimopoulos G; Herbrecht R; Drgona L; Blijlevens N J Antimicrob Chemother; 2011 Jan; 66 Suppl 1():i5-14. PubMed ID: 21177404 [TBL] [Abstract][Full Text] [Related]
16. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575 [TBL] [Abstract][Full Text] [Related]
17. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients? Salavert M Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340 [TBL] [Abstract][Full Text] [Related]